Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Sana Biotechnology, Inc. SANA NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
62/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$9.00
+158.6%

Sana Biotechnology, Inc. (SANA) is a Biotechnology company in the Healthcare sector, currently trading at $3.48. It has a SharesGrow Score of 60/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is SANA = $9 (+158.6% upside).

Valuation: SANA trades at a trailing Price-to-Earnings (P/E) of -3.3 (S&P 500 average ~25).

Net income is $244M (loss), growing at +3.1%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $79M against $161M equity (Debt-to-Equity (D/E) ratio 0.49, conservative). Current ratio is 1.89 (strong liquidity). Debt-to-assets is 18.9%. Total assets: $417M.

Analyst outlook: 9 / 11 analysts rate SANA as buy (82%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 45/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 34/100 (Fail), Future 94/100 (Pass), Income ?/100 (Fail).

$9.00
▲ 158.62% Upside
Average Price Target
Based on 11 Wall Street analysts offering 12-month price targets for Sana Biotechnology, Inc., the average price target is $9.00, with a high forecast of $12.00, and a low forecast of $7.00.
Highest Price Target
$12.00
Average Price Target
$9.00
Lowest Price Target
$7.00

SANA SharesGrow Score Overview

75/100
SharesGrow Score
Strong investment profile
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 45/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 34/100
Gross margin is + market cap
FUTURE 94/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — SANA

✓
VALUE Pass
100/100
SANA trades at a trailing Price-to-Earnings (P/E) of -3.3 (S&P 500 average ~25). Forward PEG -1.19 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $9, implying +158.6% from the current price $3. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
45/100
SANA: +0%/yr revenue is, +3.1%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet SANA: Debt-to-Equity (D/E) ratio 0.49 (conservative), Current ratio is 1.89 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
34/100
SANA: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 34/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
94/100
Analyst outlook: 9 / 11 analysts rate SANA as buy (82%). Analyst consensus target is $9 (+158.6% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range1.32-6.55
Volume16.37M
Avg Volume (30D)2.87M
Market Cap$928.7M
Beta (1Y)2.07
Share Statistics
EPS (TTM)-0.96
Shares Outstanding$253.23M
IPO Date2021-02-04
Employees194
CEOSteven D. Harr
Financial Highlights & Ratios
Gross Profit$-12.75M
EBITDA$-178.21M
Net Income$-244.17M
Operating Income$-190.96M
Total Cash$138.38M
Total Debt$78.86M
Net Debt$6.99M
Total Assets$416.89M
Price / Earnings (P/E)-3.6
Analyst Forecast
1Y Price Target$8.00
Target High$12.00
Target Low$7.00
Upside+129.9%
Rating ConsensusBuy
Analysts Covering11
Buy 82% Hold 18% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS7995661045

Price Chart

Track all markets on TradingView
SANA
Sana Biotechnology, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
1.32 52WK RANGE 6.55

People Also View

RVMD
RVMD
Revolution Medicines, Inc.
$147.01
+7.86%
 BPMC
BPMC
Blueprint Medicines Corporation
$129.46
+0.14%
 KYMR
KYMR
Kymera Therapeutics, Inc.
$89.87
+1.51%
 APLS
APLS
Apellis Pharmaceuticals, Inc.
$40.85
+0.02%
 TERN
TERN
Terns Pharmaceuticals, Inc.
$52.68
+0.13%
 MRTX
MRTX
Mirati Therapeutics, Inc.
$58.70
-0.17%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.46
-0.14%
 OLMA
OLMA
Olema Pharmaceuticals, Inc.
$16.30
+2.32%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message